
Helus Pharma rated speculative Buy ahead of key Phase 3 trial results in 2026 for depression drug HLP003.
Helus Pharma receives a speculative Buy rating due to its lead drug HLP003, an oral treatment for major depressive disorder showing promising Phase 2 results and FDA Breakthrough Therapy status. The company’s current valuation undervalues HLP003’s po...


